Cornerstone Therapeutics Inc. (CRTX) provided financial guidance for the year ending December 31, 2010.
The company anticipates net revenues in excess of $112 million in 2010. This estimate assumes that revenue contribution from branded products will increase from 40% of net revenues in 2009 to in excess of 75% of net revenues in 2010.
The company also expects GAAP net income for the year in excess of $0.6 million or $0.02 per share. Non-GAAP net income is expected in excess of $10.2 million or $0.38 per share.
For comments and feedback: editorial@rttnews.com